Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study
Abstract. Background:. To determine the prevalence and prognostic impact of hepatopulmonary syndrome (HPS) in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). Methods:. Fifty-four patients with unresectable HCC undergoing TACE between Decem...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2022-09-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002034 |
| _version_ | 1797978579891388416 |
|---|---|
| author | He Zhao Jiaywei Tsauo Xiaowu Zhang Huaiyuan Ma Ningna Weng Zhengqiang Yang Xiao Li Yuanyuan Ji |
| author_facet | He Zhao Jiaywei Tsauo Xiaowu Zhang Huaiyuan Ma Ningna Weng Zhengqiang Yang Xiao Li Yuanyuan Ji |
| author_sort | He Zhao |
| collection | DOAJ |
| description | Abstract. Background:. To determine the prevalence and prognostic impact of hepatopulmonary syndrome (HPS) in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).
Methods:. Fifty-four patients with unresectable HCC undergoing TACE between December 2014 and December 2015 were prospectively screened for HPS and were followed up for a maximum of 2 years or until the end of this prospective study.
Results:. Nineteen of the 54 (35.2%) patients were considered to have HPS, including one (5.3%) with severe HPS, nine (47.4%) with moderate HPS, and nine (47.4%) with mild HPS. The median overall survival (OS) was 10.1 (95% confidence interval [CI], 3.9–16.3) months for patients with HPS and 15.1 (95% CI, 7.3–22.9) months for patients without HPS, which is not a significant difference (P = 0.100). The median progression-free survival was also not significantly different between patients with and without HPS (5.2 [95% CI, 0–12.8] vs. 8.4 [95% CI, 3.6–13.1] months; P = 0.537). In the multivariable Cox regression analyses, carbon monoxide diffusing capacity (hazard ratio [HR] = 1.033 [95% CI, 1.003–1.064]; P = 0.028) and Child-Pugh class (HR = 1.815 [95% CI, 1.011–3.260]; P = 0.046) were identified to be the independent prognostic factors of OS.
Conclusion:. Mild or moderate HPS is common in patients with unresectable HCC undergoing TACE, but it does not seem to have a significant prognostic impact. |
| first_indexed | 2024-04-11T05:25:14Z |
| format | Article |
| id | doaj.art-b9e58c32a6e9461e91d5eaaf4ab34fd0 |
| institution | Directory Open Access Journal |
| issn | 0366-6999 2542-5641 |
| language | English |
| last_indexed | 2024-04-11T05:25:14Z |
| publishDate | 2022-09-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj.art-b9e58c32a6e9461e91d5eaaf4ab34fd02022-12-23T07:54:57ZengWolters KluwerChinese Medical Journal0366-69992542-56412022-09-01135172043204810.1097/CM9.0000000000002034202209050-00004Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort studyHe ZhaoJiaywei TsauoXiaowu ZhangHuaiyuan MaNingna WengZhengqiang YangXiao LiYuanyuan JiAbstract. Background:. To determine the prevalence and prognostic impact of hepatopulmonary syndrome (HPS) in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). Methods:. Fifty-four patients with unresectable HCC undergoing TACE between December 2014 and December 2015 were prospectively screened for HPS and were followed up for a maximum of 2 years or until the end of this prospective study. Results:. Nineteen of the 54 (35.2%) patients were considered to have HPS, including one (5.3%) with severe HPS, nine (47.4%) with moderate HPS, and nine (47.4%) with mild HPS. The median overall survival (OS) was 10.1 (95% confidence interval [CI], 3.9–16.3) months for patients with HPS and 15.1 (95% CI, 7.3–22.9) months for patients without HPS, which is not a significant difference (P = 0.100). The median progression-free survival was also not significantly different between patients with and without HPS (5.2 [95% CI, 0–12.8] vs. 8.4 [95% CI, 3.6–13.1] months; P = 0.537). In the multivariable Cox regression analyses, carbon monoxide diffusing capacity (hazard ratio [HR] = 1.033 [95% CI, 1.003–1.064]; P = 0.028) and Child-Pugh class (HR = 1.815 [95% CI, 1.011–3.260]; P = 0.046) were identified to be the independent prognostic factors of OS. Conclusion:. Mild or moderate HPS is common in patients with unresectable HCC undergoing TACE, but it does not seem to have a significant prognostic impact.http://journals.lww.com/10.1097/CM9.0000000000002034 |
| spellingShingle | He Zhao Jiaywei Tsauo Xiaowu Zhang Huaiyuan Ma Ningna Weng Zhengqiang Yang Xiao Li Yuanyuan Ji Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study Chinese Medical Journal |
| title | Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study |
| title_full | Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study |
| title_fullStr | Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study |
| title_full_unstemmed | Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study |
| title_short | Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study |
| title_sort | prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization a prospective cohort study |
| url | http://journals.lww.com/10.1097/CM9.0000000000002034 |
| work_keys_str_mv | AT hezhao prevalenceandprognosticimpactofhepatopulmonarysyndromeinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationaprospectivecohortstudy AT jiayweitsauo prevalenceandprognosticimpactofhepatopulmonarysyndromeinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationaprospectivecohortstudy AT xiaowuzhang prevalenceandprognosticimpactofhepatopulmonarysyndromeinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationaprospectivecohortstudy AT huaiyuanma prevalenceandprognosticimpactofhepatopulmonarysyndromeinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationaprospectivecohortstudy AT ningnaweng prevalenceandprognosticimpactofhepatopulmonarysyndromeinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationaprospectivecohortstudy AT zhengqiangyang prevalenceandprognosticimpactofhepatopulmonarysyndromeinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationaprospectivecohortstudy AT xiaoli prevalenceandprognosticimpactofhepatopulmonarysyndromeinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationaprospectivecohortstudy AT yuanyuanji prevalenceandprognosticimpactofhepatopulmonarysyndromeinpatientswithunresectablehepatocellularcarcinomaundergoingtransarterialchemoembolizationaprospectivecohortstudy |